SR15006
CAS 2505001-54-5
SR15006 is a inhibitor of Krüppel-like factor 5 (KLF5) with an IC50 of 41.6 nM in DLD-1/pGL4.18hKLF5p cells).
Explore bioactive compounds by research category, then narrow your search by target, product name, catalog number or CAS.
Newly added: LC-MG and OXF molecular glue research compounds →
Products may appear in more than one category. Counts refer to distinct catalog numbers within each category.
Other Research Tools (75) · Additional reagents, building blocks and specialized research tools.
LC-MG-1 (DCA0006) · LC-MG-4 (DCA0007) · LC-MG-9 (DCA0008)
View structure and evidence summaries →Combine a keyword, research category and target to narrow the product list.
Loading catalog filters…
CAS 2505001-54-5
SR15006 is a inhibitor of Krüppel-like factor 5 (KLF5) with an IC50 of 41.6 nM in DLD-1/pGL4.18hKLF5p cells).
CAS 1316059-00-3
GSK854 is a potent Inhibitor of Troponin I-Interacting Kinase (TNNI3K). GSK854 is a suitable lead for identifying new cardiac medicines and have been employed as in vivo tools in investigational studies aimed at defining the role of TNNI3K within heart failure.
CAS 2716890-91-2
CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties.
CAS 204077-66-7
Thioquinapiperifil dihydrochloride (KF31327), a potent, selective and non-competitive phosphodiesterase-5 (PDE-5, IC50 of 0.074 nM) inhibitor, is used for sexual enhancement study.
CAS 929634-33-3
Selective inhibitor of ADAMTS-5 (A disintegrin and metalloproteinase with thrombospondin motifs 5 or aggrecanase-2)
CAS 799247-52-2
Pyribencarb is a benzylcarbamate-type fungicide, which is active against a wide range of plant pathogenic fungi. Pyribencarb is a potent Qo inhibitor of cytochrome b. Pyribencarb is especially active against Botrytis cinerea and Sclerotinia sclerotirum.
CAS 897383-62-9
Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays; also inhibits ErbB4 (IC50=0.8 nM), displays >3,000-fold selectivity over other kinase families; exhibits strong antiproliferative effects on a panel of cancer cell lines, and potently suppresses tumor growth in vivo; orally available.
CAS 871026-44-7
Among the 34 kinases tested, TAK-285 only significantly inhibits HER4 with IC50 of 260 nM, slightly inhibits MEK1, MEK5, c-Met, Aurora B, Lck, CSK, and Lyn B with IC50 of 1.1 μM, 5.7 μM, 4.2 μM, 1.7 μM, 2.4 μM, 4.7 μM, and 5.2 μM, respectively, and displays no activity against other kinases with IC50 of >10 μM. TAK-285 shows significant growth inhibitory activity against BT-474 cells (HER2-overexpressing human breast cancer cell line) with GI50 of 17 nM. Compared with SYR127063 a potent inhibitor of HER2, TAK-285 displays similar in vitro potency against HER2 and EGFR. Compared with the full cytoplasmic domains of the wild-type proteins, the mutations and shortened boundaries used For structure determination of HER2-KD and EGFR-KD do not significantly change the inhibitory activity (IC50) of TAK-285. TAK-285 binds to the inactive con Formation of EGFR, and shows a similar binding mode with lapatinib in the active site. The oral bioavailability of TAK-285 is 97.7% in rats and 72.2% in mice at a dose of 50 mg/kg. Oral administration of TAK-285 at 100 mg/kg twice daily For 14 days displays significant antitumor efficacy in the HER2-overexpressing BT-474 tumor xenograft mouse model with tumor/control (T/C) ratio of 29%, without affecting body weight. Similar to the BT-474 model, TAK-285 exhibits dose-dependent tumor growth inhibition of 4-1ST (HER2-overexpressing human gastric cancer tumor) xenografts in mice, with T/C of 44% and 11% at doses of 50 mg/kg and 100 mg/kg, twice daily, respectively, without significant body weight loss in mice. Furthermore, TAK-285 treatment induces dose-dependent growth inhibition of 4-1ST tumors in rats with T/C of 38% and 14% at doses of 6.25 mg/kg and 12.5 mg/kg, and, particularly noteworthy, tumor regression with T/C of -12% and -16% at doses of 25 mg/kg and 50 mg/kg, respectively. After oral administration of TAK-285, a significant amount of TAK-285 is present in the brain of rats in pharmacologically active, unbound Form (approximately 20% of its free plasma level), indicating that TAK-285 has a potential in the therapy of CNS malignancies/metastases. For the detailed information of TAK-285, the solubility of TAK-285 in water, the solubility of TAK-285 in DMSO, the solubility of TAK-285 in PBS buffer, the animal experiment (test) of TAK-285, the cell expriment (test) of TAK-285, the in vivo, in vitro and clinical trial test of TAK-285, the EC50, IC50,and Affinity of TAK-285, Please contact DC Chemicals.
CAS 354126-20-8
CID1231538, a benzothiazole analogue, is a potent GPR35 antagonist (IC50=0.55 μM). GPR35 is a G protein-coupled receptor (GPCR).
CAS 1127498-03-6
For the detailed information of JNJ40411813, the solubility of JNJ40411813 in water, the solubility of JNJ40411813 in DMSO, the solubility of JNJ40411813 in PBS buffer, the animal experiment (test) of JNJ40411813, the cell expriment (test) of JNJ40411813, the in vivo, in vitro and clinical trial test of JNJ40411813, the EC50, IC50,and Affinity of JNJ40411813, Please contact DC Chemicals.
CAS 406191-34-2
BCATc Inhibitor 2 is a selective branched-chain aminotransferase (BCAT) inhibitor for research of neurodegenerative diseases. The IC50s of 0.2 μM, 0.8 μM and 3.0 μM for rat cytosolic isoenzyme rBCATc, human cytosolic isoenzyme hBCATc and rat mitochondrial isoenzyme rBCATm, respectively.
CAS 2089293-61-6
In Vitro NAcM-OPT (Compound 67) is orally bioavailable, well tolerated in mice, and currently used to study the effects of acute pharmacologic inhibition of the DCN1-UBE2M interaction on the NEDD8/CUL pathway.
CAS 1928763-08-9
The first potent, selective, CNS penetrating inward rectifier potassium channel Kir7.1 (KCNJ13) inhibitor with IC50 of 0.31 uM; displays >17-fold selective over Kir1.1, Kir2.1, Kir2.2, Kir2.3, Kir3.1/3.2, and Kir4.1 except for Kir6.2/SUR1 (equally potent); possesses a DMPK profile suitable for both in vitro and in vivo studies aimed at modulating both peripheral and central Kir7.1 potassium channels.
CAS 1257051-63-0
THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species.
CAS 747408-78-2
PBT 1033 (PBT 2) is an orally active copper/zinc ionophore. PBT 1033 restores cognition in mouse models of Alzheimer's disease (AD). PB 1033 also has antibacterial activity against Gram-positive bacteria.
CAS 383907-43-5
NSC 663284 is a Cdc25 dual specificity phosphatases inhibitor with an IC50 of 0.21 μM.
CAS 474432-66-1
FAUC 365 is a highly dopamine D3 receptor-selective antagonist with Ki values of 0.5 nM, 340, 2600, and 3600 nM at D3, D4.4, D2short, and D2Long receptors, respectively. FAUC 365 can be used for the research of schizophrenia, and Parkinson's disease.
CAS 2485052-87-5
TR-107 (TR107) is a highly potent, selective and orally bioavailable small-molecule activator of the mitochondrial protease ClpP with EC50 of 140 nM, binds to purified ClpP with Kd value of 180 nM in surface plasmon resonance (SPR) measurement.
CAS 371215-02-0
OGT-IN-1 (Compound 5) is a potent OGT inhibitor. OGT-IN-1 inhibits sOGT and ncOGT with IC50s of 27 and 10 μM, respectively.
CAS 183499-57-2
L-778123 is a dual FPTase and GGPTase-I inhibitor, with IC50s of 2 nM and 98 nM respectively.
CAS 2377604-81-2
CHMFL-PI4K-127 (compound 15g) is an orally active, potent and high selective PfPI4K (Plasmodium falciparum PI4K kinase) inhibitor, with an IC50 of 0.9 nM. CHMFL-PI4K-127 exhibits potent activity against 3D7 Plasmodium falciparum, with an EC50 of 25.1 nM. CHMFL-PI4K-127 shows antimalaria efficacy.
CAS 1394894-41-7
JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor.
CAS 1025821-33-3
GSK-626616 is a dual-specificity tyrosine-regulated kinase (DYRK3) inhibitor with an IC50 of 0.7 nM which is a potential therapy for the treatment of anemia.
CAS 1416775-08-0
Vevorisertib (ARQ 751) (trihydrochloride) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). Vevorisertib (trihydrochloride), as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations.
CAS 2377491-54-6
AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease.
CAS 2863686-82-0
Compound X1 (Xist) X1 (Xist) binds the non-coding RNA prototype Xist, specifically the RepA motif, with Kd of 0.4 μM. X1 binding reduces the conformational space of RepA, displaces cognate interacting protein factors (PRC2 and SPEN), suppresses histone H3K27 trimethylation, and blocks initiation of X-chromosome inactivation.
CAS 64821-19-8
MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible MAO-A (IC50=37 nM) and MAO-B (IC50=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease.
CAS 2085274-00-4
Antifungal agent 35 (compound 24) is a potent antifungal agent. Antifungal agent 35 is a potent enhancer of antifungal activity of Fluconazole against C. albicans.
CAS 1845777-61-8
PI3K-IN-20 is a PI3k inhibitor extracted from WO2017101847 A1, compound 1.
CAS 2388506-44-1
MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).
CAS 903895-98-7
FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist.
CAS 151271-08-8
GABA-A modulator, blocking the sedative effects without lowering the convulsion threshold
CAS 147751-31-3
HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC50 = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease.
CAS 1215010-55-1
DDD 85646 is a potent, specific, dual N-Myristoyltransferase NMT1/NMT2 inhibitor with IC50 of 17 nM/22 nM respectively; inhibits myristoylation of an overexpressed protein construct in-cell-based microscopy assays; has no significant affect protein synthesis in cells; causes complete inhibition of N-myristoylation in cells at 1-10 uM; induces ER-stress, cell cycle arrest, and apoptosis in cancer cells.
CAS 161314-17-6
NNGH is a stromelysin-1 (MMP-3) inhibitor. MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/β-catenin signaling pathway. Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression.
CAS 1380317-28-1
Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis.
CAS 2439277-80-0
IDE-397 (GSK-4362676, GSK-676) is a potent, selective small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor, displays broad anti-tumor activity across a panel of MTAP-deleted patient-derived xenografts.
CAS 2444764-03-6
In Vitro GKI-1 inhibits full-length human GWL, and shows cellular efficacy. Treatment of HeLa cells (25 and 50 µM) with GKI-1 reduces ENSA/ARPP19 phosphorylation levels, resulting in a decrease in mitotic events, mitotic arrest/cell death and cytokinesis failure.
CAS 847163-23-9
NCGC 00067819 is a small molecule compound that potentiates CREB signaling with EC50 of 16 nM in the primary screen and 79 nM in the CHO CRE-β-lactamase confirmation assay; potentiates cAMP production induced by NKH 477.
CAS 1380716-06-2
Novel glucocerebrosidase activator; Non-inhibitory chaperones of glucocerebrosidase
CAS 2413739-88-3
Evifacotrep, a short transient receptor potential channel 5 (TRPC5) antagonist (WO2020061162, compound 100), can be used for the research of neurological diseases.
CAS 1417823-67-6
REM0046127 (REM127) is a ReS19-T compound and restores calcium homeostasis and neutralizes tau- and Aβ-driven neurotoxicity. REM127 reduces toxicity and [Ca2+]cyto with EC50 of 15 and 19 nM, respectively but has no effect on tau expression or ATRA-dependent gene transcription.
CAS 932359-76-7
FiVe1 is a vimentin binding small molecule that promotes vimentin disorganization and phosphorylation during metaphase, causes mitotic catastrophe, multinucleation, and the loss of stemness in cancer cells.
CAS 53772-83-1
Zuclopenthixol ((Z)-Clopenthixol) is a thioxanthene derivative which acts as a mixed dopamine D1/D2 receptor antagonist.
CAS 208110-64-9
Befiradol (F13640, NLX 112) is a highly potent, selective 5-HT1A receptor agonist with Ki of 2.7 nM; exhibits agonist efficacy greater than for (±)8-OH-DPAT or buspirone; stimulates 'total G-proteins', but unlike (±)8-OH-DPAT and buspirone, more potent for Gαo activation, in rat hippocampal membranes; dose-dependently decreases extracellular 5-HT in the hippocampus and mPFC in rats, activates both 5-HT(1A) autoreceptors and postsynaptic 5-HT(1A) receptors in prefrontal cortex with a similar potency. Pain Discontinued